Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar:73:1-6.
doi: 10.1016/j.ejim.2019.12.014. Epub 2020 Jan 16.

Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life

John R Hurst  1 , Neil Skolnik  2 , Gerald J Hansen  3 , Antonio Anzueto  4 , Gavin C Donaldson  5 , Mark T Dransfield  6 , Precil Varghese  7
Affiliations
Free article
Review

Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life

John R Hurst et al. Eur J Intern Med. 2020 Mar.
Free article

Abstract

Exacerbations of chronic obstructive pulmonary disease (COPD) represent a significant clinical problem, and are associated with decreased lung function, worsening quality of life and decreased physical activity levels, with even a single exacerbation having detrimental effects. The occurrence of COPD exacerbations can also have a considerable impact on healthcare costs and mortality rates, with over one-fifth of patients hospitalized for a COPD exacerbation for the first time dying within one year of discharge. This highlights the need for COPD exacerbations to be a major focus in clinical practice. Furthermore, the substantial effect that COPD exacerbations can have on patient mental health should not be underestimated. Despite their clinical importance, COPD exacerbations are poorly recognized and reported by patients, and improving patient understanding and reporting of exacerbations to ensure prompt treatment may minimize their deleterious effects. Renewed focus on improving current clinical practice with support from evidence-based guidelines is required. This also raises a challenge to payors, healthcare systems and government policies to do more to tackle the considerable outstanding burden of COPD exacerbations.

Keywords: Comorbidity; Mental health; Mortality; Physical functional performance; Quality of life; Respiratory function tests.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest J.R. Hurst reports grants, personal fees and non-financial support from pharmaceutical companies that make medicines to treat COPD. N. Skolnik reports nonfinancial support from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Sanofi; personal fees from AstraZeneca, Boehringer Ingelheim and Eli Lilly; and has served on advisory boards for AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Intarcia, Janssen Pharmaceuticals, Merck, Mylan, Sanofi and Teva Pharmaceutical. G.J. Hansen reports no conflicts of interest. A. Anzueto reports grants or fees from AstraZeneca, Boehringer Ingelheim, Forest Laboratories, GlaxoSmithKline and Novartis. G.C. Donaldson reports personal fees from the American Thoracic Society, AstraZeneca, Micom Ltd and the Research Foundation Flanders (FWO) outside the submitted work. M.T. Dransfield reports grants from the American Lung Association, the Department of Defense, the Department of Veterans Affairs and the National Heart, Lung, and Blood Institute; personal fees from Mereo and Quark; personal fees and other from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and PneumRx; and other from Boston Scientific, Pulmonx, Novartis and Yungjin. P. Varghese is an employee of AstraZeneca.

Publication types

LinkOut - more resources